Theodora Fynn, MD
Pulmonary Disease · Newark, DENPI 1205093804
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 93 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 18.8% — the pattern of someone who eats at a lot of different presentations.
Across 93 payments — averaging $18.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$320
- AstraZeneca$261
- Boehringer Ingelheim$205
- Grifols USA, LLC$132
- Regeneron Healthcare Solutions, Inc.$129
- Insmed, Inc.$87
- plus $571 from 22 others
What the payments were for
- Food & beverage$1,697100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 18 | $320 |
| AstraZeneca(2 entities) | 16 | $261 |
| Boehringer Ingelheim | 14 | $205 |
| Grifols USA, LLC | 5 | $132 |
| Regeneron Healthcare Solutions, Inc. | 4 | $129 |
| Insmed, Inc. | 4 | $87 |
| Verona Pharma, Inc. | 3 | $47 |
| Sunovion Pharmaceuticals Inc. | 3 | $46 |
| Vifor Pharma, Inc. | 2 | $45 |
| Jazz Pharmaceuticals Inc. | 3 | $42 |
| Electromed, Inc. | 2 | $40 |
| Mylan Specialty L.p. | 2 | $37 |
| Genentech USA, Inc. | 2 | $37 |
| Harmony Biosciences LLC | 1 | $31 |
| Sanofi | 1 | $25 |
| Viatris Specialty LLC | 1 | $25 |
| Inspire Medical Systems, Inc. | 1 | $20 |
| Mallinckrodt Hospital Products Inc. | 1 | $19 |
| Fisher & Paykel Healthcare Inc | 1 | $19 |
| Lilly USA, LLC | 1 | $19 |
| Shire North American Group Inc | 1 | $18 |
| Novartis | 1 | $16 |
| Mallinckrodt Enterprises LLC | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
| United Therapeutics Corporation | 1 | $15 |
| Resmed Corp | 1 | $14 |
| Circassia Inc. | 1 | $14 |
| Pfizer | 1 | $12 |
How this compares
$1,704 in reported general payments places this provider in the 60th percentile of 39 pulmonary disease providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Newark
- Albert RizzoNewark$162K
- Haroon RajaNewark$44K
- Ismael MatusNewark$27K
- Naveed HasanNewark$3K
- Sam ThomasNewark$2K
- Irene SwiftNewark$2K
- Donald CollinsNewark$2K
- Sajjad AhmadNewark$749
- Sonali BishnoiNewark$686
- Farid MoosavyNewark$615
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.